Compare · BDMD vs BSX
BDMD vs BSX
Side-by-side comparison of Baird Medical Investment Holdings Ltd (BDMD) and Boston Scientific Corporation (BSX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BDMD and BSX operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BSX carries a market cap of $60.90B.
- Over the past year, BDMD is down 67.8% and BSX is down 39.2% - BSX leads by 28.6 points.
- BDMD has been more active in the news (6 items in the past 4 weeks vs 3 for BSX).
- BSX has more recent analyst coverage (25 ratings vs 0 for BDMD).
- Company
- Baird Medical Investment Holdings Ltd
- Boston Scientific Corporation
- Price
- $1.85+8.19%
- $62.06-5.52%
- Market cap
- -
- $60.90B
- 1M return
- -15.91%
- -11.05%
- 1Y return
- -67.83%
- -39.23%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 6
- 3
- Recent ratings
- 0
- 25
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
Latest BDMD
- SEC Form 20-F filed by Baird Medical Investment Holdings Ltd
- SEC Form 3 filed by new insider Xu Lijian
- SEC Form 3 filed by new insider Qiu Quan
- SEC Form 3 filed by new insider Lu Rongjian
- SEC Form 3 filed by new insider Bilciu-Wolfson Gabrielle
- SEC Form 3 filed by new insider Li Jie Clara
- SEC Form 3 filed by new insider Ragan Joseph Douglas Iii
- SEC Form 3 filed by new insider Hou Wei
- SEC Form 3 filed by new insider Wu Haimei
- Baird Medical Advances Clinical Education with Expert-Led Workshops in Indonesia
Latest BSX
- Data at Heart Rhythm 2026 highlight key Boston Scientific therapies
- Boston Scientific Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Boston Scientific announces results for first quarter 2026
- SEC Form EFFECT filed by Boston Scientific Corporation
- SEC Form 424B3 filed by Boston Scientific Corporation
- Boston Scientific downgraded by Raymond James with a new price target
- Boston Scientific announces conference call discussing first quarter 2026 results
- Amendment: SEC Form S-4/A filed by Boston Scientific Corporation
- Boston Scientific Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- CHAMPION-AF study of the WATCHMAN FLX™ Left Atrial Appendage Closure Device as a first-line therapy for stroke risk reduction meets all primary and secondary safety and efficacy endpoints